Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

By Heikki Joensuu, P. Kellokumpu-Lehtinen, P. Bono, T. Alanko, V. Kataja, R. Asola, T. Utriainen, R. Kokko, A. Hemminki, M. Tarkkanen and 14 more. New England Journal of Medicine, 2006

1,326 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/7e530a31d01bcdaacb8b7d27744c8e2e18f847c8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. (2012, background): “HERA, n = 5,102 [20] Adj chemo ≥H versus Adj”
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 (2009, methodology): “Although the definitions used in the pivotal trials of trastuzumab were less restrictive [81–84], a substantial minority of the Panellists preferred to use 30% intense and complete staining as a threshold for recommendation of anti-HER2 therapy.”
Trastuzumab--mechanism of action and use in clinical practice. (2007, background): “New Zealand funds the concurrent 9-week FinHer regimen[5] described by Dr.”
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (2007, background): “Subsequently, five randomized trials have demonstrated a benefit for trastuzumab in ERBB2 + patients with breast cancer receiving adjuvant chemotherapy after local regional treatment for a primary tumou”
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, methodology): “A shorter duration (9 weeks) as used in the FinHER study [92] was not generally accepted.”
Parallel progression of primary tumours and metastases (2009, background): “and seems to cure a substantial proportion of M0 stage patients with ERBB2-positive breast cance”
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, methodology): “In most studies, trastuzumab was administered for 1 year, although in the FinHER trial a similar improvement was obtained with only 9 weeks of treatment [II, A] [91].”
Treatment of HER2-positive breast cancer: current status and future perspectives (2012, result): “The FinHER study has already provided evidence that 9 weeks of adjuvant trastuzumab (given concurrently with chemotherapy) has improved efficacy in terms of distant relapse-free survival compared with chemotherapy alone, but this was not compared with the standard 1-year duration of trastuzumab trea”
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, neutral): “which demonstrated that one year of trastuzumab therapy provided significant clinical benefit [63–66].”